Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
Anatara Lifesciences is pleased to announce that it has received a second payment under the exclusive Research Evaluation and License Option Agreement with the global animal health company, Zoetis Inc., to explore the utility of Detach™ a non-antibiotic anti-infective product, for use in food production animals.
Please click here to view the ASX announcement.
NDF Research’s Initiation of Coverage Research & Valuation Report
NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.
Please click here to view the report.